Literature DB >> 2777202

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

A K Batta1, G Salen, R Arora, S Shefer, G S Tint, J Abroon, D Eskreis, S Katz.   

Abstract

We have compared the effect of ursodeoxycholic acid with placebo on the clinical state, blood liver chemistries and serum and urinary bile acids in four patients with primary biliary cirrhosis. All parameters were evaluated monthly, and bile acid composition was measured by capillary gas-liquid chromatography. At the time of admission, all patients showed intense pruritus, and their serum alkaline phosphatase, AST and ALT levels were elevated 4.3, 2.7 and 2.3 times over control values. Serum bile acids were elevated almost 38-fold with 2.5 times more cholic acid than chenodeoxycholic acid. Urinary bile acid output was elevated 28 times the control values, and 36% were 1 beta-hydroxycholic acid, 1 beta-hydroxydeoxycholic acid and hyocholic acid (3 alpha,6 alpha, 7 alpha-trihydroxy-5 beta-cholanoic acid). Three months of placebo administration did not significantly affect the clinical or biochemical presentations, and the serum and urinary bile acid composition did not change. In contrast, ursodeoxycholic acid feeding (12 to 15 mg per kg per day) for 6 months abolished pruritus in two and lessened itching in two subjects and reduced serum alkaline phosphatase, AST and ALT levels by 21, 35 and 47%, respectively. The mean values for the total serum bile acid concentrations in these patients declined 26% from the pretreatment value, but the proportion of ursodeoxycholic acid increased from 3 to 40% of the total bile acids; thus, total fasting serum endogenous bile acid levels decreased almost 50%. Similar changes were noted in the urinary bile acids, in which ursodeoxycholic acid became the major bile acid, and approximately 18% were hydroxylated at C-1, C-6 and C-21.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777202     DOI: 10.1002/hep.1840100404

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

1.  The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.

Authors:  T Higuchi; N Hishida; T Isomura; H Takeshima; H Hayashi
Journal:  Gastroenterol Jpn       Date:  1992-04

2.  Influence of cholestasis on absorption of ursodeoxycholic acid.

Authors:  P Sauer; C Benz; G Rudolph; P Klöters-Plachky; W Stremmel; A Stiehl
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

Authors:  G Rudolph; D N Gotthardt; P Kloeters-Plachky; H Kulaksiz; P Schirmacher; A Stiehl
Journal:  Dig Dis Sci       Date:  2011-06-09       Impact factor: 3.199

Review 4.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 5.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

6.  Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.

Authors:  Emmanouil Sinakos; Hanns-Ulrich Marschall; Kris V Kowdley; Alex Befeler; Jill Keach; Keith Lindor
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

7.  Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.

Authors:  K D Setchell; C M Rodrigues; M Podda; A Crosignani
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

Review 8.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

9.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Ursodeoxycholic acid in chronic liver disease.

Authors:  J S de Caestecker; R P Jazrawi; M L Petroni; T C Northfield
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.